Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL

  • Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma
  • Hensify®–a first-in-class radioenhancer–offers cancer patients an innovative

Post Author: Asianet Pakistan